top of page


Flashback BioRN Annual Conference 2023:  

Next Generation Cell and Gene Therapy


After many decades of effort, the future of gene and cell therapies is incredibly promising. While these technologies were initially developed in the context of treating rare diseases caused by a single faulty gene, a variety of gene and cell-based therapies for both rare and common diseases are currently in development. In addition, dedicated resources, facilities and expertise are evolving to scale up and work towards the clinical development and the commercial production.

Since 2009, each year the BioRN Annual Conference has been a valuable source of top information, lively discussions and networking opportunities with international experts from different fields of the life sciences.

We are close to huge breakthroughs in a new field of medicine that would create a new paradigm for healthcare.

 Sponsors 2023





Exhibitors 2023


ARXUM® is a deep-tech blockchain technology company offering advanced infrastructure and versatile middleware that reduces the complexity of connecting existing IT systems with blockchain-based business logic. This enables highly complex, global and cross-enterprise industrial processes to run across heterogeneous IT systems in a completely transparent, tamper-proof and stable manner.

The solutions offered by ARXUM® are applied in the areas of pharmaceuticals, procurement, logistics, manufacturing and sales. The basis for this is an innovative solution suite based on state-of-the-art blockchain technology and deep industrial know-how.

Trusted by a wide range of organizations, from cutting-edge startups right up to big pharma, our success is founded on purpose-built and future-ready solutions.


BioEcho Life Sciences is a specialized solution provider for the extraction and analysis of nucleic acids. We create disruptive technologies, products, and workflows that make downstream processing of nucleic acids easier and faster, significantly increase throughput, and deliver reliable results. Our patented EchoLUTION™ technology enables the fastest DNA and RNA extraction on the market - in just one single step. It reduces the associated plastic consumption by up to 70 %.
BioEcho was founded in 2016 by leading industry experts. The headquarter in Cologne, Germany, is certified according to ISO 9001 and ISO 13485. 

BioEcho. The Nucleic Acid Experts.

BioIVT Logo wix.png

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, we specialize in control and disease state samples including human and animal tissues or preparations, cell and gene therapy products, blood, and other biofluids, as well as ADME contract research services from standalone bioanalytical support through tiered in vitro studies with submission-ready reports to customized consulting.
By combining our technical expertise, exceptional customer service, and unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.

Biolabs wix.png

BioLabs are the premier co-working spaces for life science startups — unique places where you can test, develop and grow your game-changing ideas. As entrepreneurs and investors ourselves, we have firsthand experience with the pain points biotech startups face. Our goal is to change how scientific entrepreneurs do business by building an ecosystem that empowers bioinnovators to grow quickly, while maximizing capital efficiency.

CellSignal wix.png

Founded by research scientists in 1999, Cell Signaling Technology (CST) is a private, family-owned company with over 400 employees worldwide. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies with high levels of specificity and lot-to-lot consistency. That’s why we produce all of our antibodies in house and perform painstaking validations for multiple applications. And the same CST scientists who produce our antibodies also provide technical support for customers, helping them design experiments, troubleshoot, and achieve reliable results.


The GxP document management and collaboration platform for pharmaceutical and biotech companies that enables seamless collaboration with third parties With Docuply, we enable pharmaceutical and biotech companies to run smooth and GxP-compliant day-to-day operations with third parties and distributed teams. This way, you avoid chaotic audits and downtime during an inspection. Ultimately, this leaves more time for what matters most: Making the world a little better with new medicines.


GenScript Biotech (Netherlands) B.V. is a leading life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions.

GenScript Probio.png

GenScript ProBio, a subsidiary of GenScript Biotech Corporation, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, vaccine and antibody protein drug, aiming to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, and China (Hong Kong, Shanghai, and Nanjing) and other regions to serve global customers, and has helped customers in the United States, Europe, Asia Pacific and other regions obtain more than 50 IND approvals since October 2017.

GenScript ProBio’s total CGT solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing. GenScript ProBio’s innovative solutions for biologics discovery and development include therapeutic antibody discovery, antibody engineering and antibody characterization. In the biologics CDMO service, GenScript ProBio has built a DNA to GMP material platform, including stable cell line development, host cell commercial license, process development, analytical development to clinical and commercial manufacturing, and offer fed-batch and perfusion processes to meet the growing needs for antibody and protein drugs. GenScript ProBio has established GMP capacity that meets regulatory requirements of the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and National Medical Products Administration (NMPA).


Gerresheimer is the global partner for pharmaceutics, biotech and healthcare with a very broad product range for pharmaceutical packaging solutions and drug delivery systems. 
The company is an innovative solution provider from concept to delivery of the end product, with 11,000 employees, locations all around the globe and 36 manufacturing sites.

The division Gx Biological Solutions is especially dedicated to leverage the entire organization capabilities to serve its customers, from the lab to the patient 
incl. life cycle management and associated services along the journey of clinical phases. 
The experts of Gx Biological Solutions are designing the best containment and delivery strategy for successful drug development when related to primary packaging and drug delivery systems. 
It includes glass and COP platforms (vials & pre-filled syringes), delivery systems (syringes, auto-injectors, on-body devices) and associated services (compatibility, E&L, regulatory, …). 
Gx Biological Solutions is the go to partner to increase patient adherence and facilitate your drug development journey from early stage to clinical phases.


Heidelberg ImmunoTherapeutics GmbH is a clinical stage biopharmaceutical company focusing on the clinical development of innovative antibody-based immunotherapeutic for the treatment of viral diseases and cancer.

The company was founded as spin-off from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital in 2016. Our goal is to advance novel immunotherapeutic from preclinical research towards early phase I and II clinical trials. The company’s lead product, HDIT101, is designed to treat herpes simplex virus infections, which affect millions of people. An initial human study demonstrating the pharmacokinetics, safety and tolerability has been completed. Two phase II studies are currently ongoing in patients with recurrent HSV-2 positive genital herpes and in patients with orolabial HSV-1 infections.


Medical technology is an essential and innovative sector within the healthcare industry on which the city of Mannheim has set a focus to support the emergence of new medical products and the establishment and growth of companies. In 2011 the city launched the Mannheim Medical Technology Cluster which supports the networking of companies, startups, clinics, universities and research institutes in the region. The Cluster includes players in all subsectors of the healthcare industry within an hour’s drive of Mannheim, aiming to work on the further development of innovation and the ecosystem. The Cluster Office is located on the Mannheim Medical Technology Campus which offers space for young, innovative companies – an area right beside the University Hospital of Mannheim. The strategic planning is managed by the Executive Board, including representatives of the city of Mannheim, as well as managing directors and executives of local and regional medtech companies, the Mannheim Medical Faculty of the University of Heidelberg, Mannheim University of Applied Sciences, the Institute of Medical Technology and the Fraunhofer Institute.

Metropolregion Rhein-Neckar.png

The Rhine‐Neckar metropolitan region with its 2.4 million inhabitants is one of Germany’s most vital locations for business. The region ranks highly with its innovative spirit, reputation for academic excellence, a lively cultural scene, attractive options for living and shopping, striking and unspoiled natural resources and the can‐do attitude of its local citizens. It is home to global businesses such as BASF, SAP and Bilfinger, along with SMEs and start‐ups. In fact, the Rhine‐Neckar triangle is a hot spot for business incubators; there are 15 such centres in the greater Heidelberg, Mannheim and Ludwigshafen areas alone. The core areas of industry for the region include biotech, IT, chemicals, automotive, mechanical engineering and systems engineering, plus a vital cultural and creative economy. An excellent local infrastructure combined with its location at the heart of Europe ensure the region enjoys optimum connections to networks of all kinds. Its huge capacity for innovation is built on a high level of education; Rhine‐Neckar is among the top locations when it comes to highly qualified workers, and 16.7% of employees work in high‐tech industries. The 22 universities and some 30 internationally renowned research institutes in the region maintain close contact with industry and thereby ensure broad transfer of knowledge.


BIMOVIS is an innovative startup with the ambition to make structural biology easily accessible to small and medium sized companies.

Large companies often have a separate department for structural biology providing expertise for drug
design, protein engineering, development of analytical methods, interpretation of special publications and marketing. For startups and SMEs, it is usually not economical to employ structural biologists and bioinformaticians, which represents a clear competitive disadvantage.
With BIMOVIS, we aim to close this gap and help companies utilize structural biology depending on the available resources. In addition to consultation and project coordination, we support our clients with tailor made training and courses to acquire internal expertise in the field of structural biology. Thus, our customers become increasingly independent in structural biology and ultimately more professional in protein science.


PROGEN was founded in 1983 by four scientists from Heidelberg, Germany, who joined forces to manufacture and supply high quality antibodies for biomedical research.

We help scientists worldwide drive biopharmaceutical and diagnostic progress to provide high-quality and reliable treatments for patients. Our mission is to make new therapies safe and affordable and to improve existing research processes.

The PROGEN team consists of bioscientists and adeno-associated virus (AAV) experts who collaborate with specialists around the world. Our products are essentials for research in science and industry.

We are more than just a manufacturer of antibodies, AAV gene therapy tools, density gradient media, and phage display technologies: We strive to understand the needs of scientists to develop solutions to jointly address challenges in academic research, biotechnology and pharma.


With a portfolio of more than 4,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in academic, industrial and government settings. Promega products are used by life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification. Since its founding in 1978, Promega has consistently integrated the values of corporate responsibility and sustainable business practices into all aspects of its corporate culture and activity. Promega realizes that its success depends upon the connections the company forges among its customers, community and employees.

Since 1997 and with about 100 employees, Promega GmbH, as a subsidiary of the Promega Corp. is responsible for the distribution of Promega products in Germany, Austria, Poland and Eastern Europe.


ProtaGene CGT GmbH (former GeneWerk GmbH) is part of the world-leading analytic CRO ProtaGene which is partner for the biopharmaceutical and cell and gene therapy industries. As pioneers and industry leaders, we are setting the standards for vector safety and integration site analysis in preclinical and clinical development of gene therapies. Our strong bioinformatics as well as research and development capabilities complement the portfolio needed by our clients. GeneWerk’s founders were leading experts in the field and involved in the safety assessment of many cell and gene therapy drug products, including Glybera®, the first gene therapy drug product approved in the western countries for treating Lipoprotein Lipase Deficient (LPLD).

For more than 20 years, the team has worked alongside clients around the world and from research through product commercialization to develop novel cell and gene therapies that meet regulatory safety requirements. Our clients rely on our deep scientific, technical and regulatory expertise to de-risk their cell and gene therapy development pathway.

As a credible partner with proven expertise in the field, we function as an extension to the client’s internal teams to bring breakthrough therapies in development to market authorization.

Schott wix.png

SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. The portfolio comprises drug containment and delivery solutions for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 65 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house, a state-of-the-art R&D center in Switzerland, and around 130 employees in R&D, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA, headquartered in Mainz, Germany, is part of SCHOTT AG that is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. 

VIB logo wix.png

Access to cutting-edge technology is key in modern life science to accelerate scientific discoveries. VIB Technologies has a unique approach which provides its research community a competitive advantage by offering access to state-of-the art technologies. 
This technology access is enabled by supporting the entire technology uptake flow, starting with mediating early access to technologies elaborated by Tech Watch.
Validated technologies by Tech Watch’s Innovation lab, are implemented within VIB Core Facilities. The VIB Cores are facilitating access to top-notch technologies and offer all-in fee-for services, supported by skilled expert technologists. VIB Cores continue on improving implemented technologies by collaborations giving new approaches and by increasing sample throughput via automation. 
Next to services, consultancy and support, VIB Technologies shares also its expertise and knowledge through VIB Technology Training. 

TK Logo.jpg

Founding is a great thing! Everyone improves our world a little bit in their own way. 
In doing so, you need full attention for your innovation. 

But especially during the growth phase, questions like the following often get in your way: 

What’s happening with my insurance when I’m self-employed?
Who can help with my questions all about social insurance?
What do I need to consider when hiring new employees? 
My employees demand benefits, but I have no budget for that, what should I do?

We have the right answer to all of these questions, of course tailored to your individual situation! 


YUMAB develops fully human antibodies from target to lead for clients and partners worldwide.
Its proprietary antibody platform covers all technologies from antibody discovery – using one of the world’s largest, natural human antibody library collection (>10e11) or customized, patient-derived or immune  libraries – to antibody engineering and lead optimization.
YUMAB antibodies contain natural, close to germ-line sequences promising low immunogenicity and toxicity. The advanced in vitro and on-cell selection technologies pre-design antibody properties, such as interspecies X-reactivity and developability, early in the development process and provide high success-rates to all types of antigens, including difficult targets like GPCRs or ion channels. Bioinformatic optimization and in vitro evolution technologies provide a direct path towards optimized lead candidates for all antibody drug formats such as full-length IgG, Fab, scFv, bispecifics, CARs, fusion proteins and ADCs.

bottom of page